AI assistant
Aldeyra Therapeutics, Inc. — Director's Dealing 2017
Jun 12, 2017
33278_dirs_2017-06-12_9b4f2014-3b13-40e8-b10b-a01aa974c683.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aldeyra Therapeutics, Inc. (ALDX)
CIK: 0001341235
Period of Report: 2017-06-08
Reporting Person: JOYCE MARTIN JOSEPH (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-08 | Stock Option (Right to Buy) | $5.15 | A | 17776 | Acquired | 2027-06-07 | Common Stock (17776) | Direct |
| 2017-06-08 | Stock Option (Right to Buy) | $5.15 | A | 4444 | Acquired | 2027-06-07 | Common Stock (4444) | Direct |
| 2017-06-08 | Stock Option (Right to Buy) | $5.15 | A | 1037 | Acquired | 2027-06-07 | Common Stock (1037) | Direct |
Footnotes
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.